KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $108.0 million.

  • Bristol Myers Squibb's Non Operating Income rose 14615.38% to $108.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 37465.44%. This contributed to the annual value of -$893.0 million for FY2024, which is 17711.57% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's Non Operating Income stood at $108.0 million, which was up 14615.38% from -$494.0 million recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Non Operating Income peaked at $702.0 million during Q1 2021, and registered a low of -$649.0 million during Q1 2022.
  • Its 5-year average for Non Operating Income is -$16.6 million, with a median of $2.0 million in 2021.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 1430000.0% in 2022, then surged by 16363.64% in 2023.
  • Bristol Myers Squibb's Non Operating Income (Quarter) stood at -$393.0 million in 2021, then skyrocketed by 155.22% to $217.0 million in 2022, then skyrocketed by 70.97% to $371.0 million in 2023, then crashed by 182.21% to -$305.0 million in 2024, then soared by 135.41% to $108.0 million in 2025.
  • Its Non Operating Income stands at $108.0 million for Q3 2025, versus -$494.0 million for Q2 2025 and -$339.0 million for Q1 2025.